ArticleJournal of community genetics2026
Trends in awareness and uptake of genetic testing among the United States population, 2011-2022.
Article in Journal of community genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
While genetic testing (GT) has become more available over the past decade, it is unclear whether public awareness and use have increased proportionally. We aimed to evaluate national trends in GT awareness and usage. We performed a cross-sectional analysis of nationally representative data from the National Cancer Institute's Health Information National Trends Survey (HINTS). We analyzed survey responses from HINTS 4 Cycle 1-4 (2011-2014), 5 Cycle 1 and 4 (2017, 2020), and 6 (2022). Primary outcomes were overall genetic testing awareness and uptake. Secondary analyses evaluated awareness and uptake of health-related genetic testing (e.g. disease risk, cancer, and carrier testing) among survey cycles in which specific testing modalities were available. Linear regression assessed crude trends and multivariable logistic regression estimated odds ratios (OR). Among 22,256 respondents, overall awareness of GT increased from 36.6% in 2011 to 81.7% in 2022 (trend p < .001). Awareness was lower among individuals who were older (e.g., ref: age 18-34, age 75+: OR 0.53, 95% confidence interval [CI]: 0.43-0.64), male (ref: female, OR 0.85, CI: 0.77-0.95), non-Hispanic Black (ref: non-Hispanic White, OR 0.63, CI: 0.54-0.74), non-Hispanic Asian (ref: non-Hispanic White, OR 0.38, CI: 0.29-0.48), Hispanic (ref: non-Hispanic White, OR 0.60, CI: 0.52-0.69), with less than a college education (e.g., ref: some college, less than high school: OR 0.60, CI: 0.47-0.77), and with annual household income <$75,000 (e.g., ref: >$75,000, <$20,000: OR 0.49, CI: 0.42-0.59). GT uptake increased from 21.4% in 2020 to 35.6% in 2022 (trend p < .001). GT uptake was lower among individuals who were non-Hispanic Asian (ref: non-Hispanic White, OR 0.60, CI: 0.38-0.96) and had household incomes <$35,000 (e.g., ref: >$75,000, <$20,000: OR 0.68, CI: 0.49-0.94), but higher among those with a personal history of cancer (ref: no cancer history, OR 1.44, CI: 1.07-1.92). Although GT awareness has grown, there are notable gaps across sociodemographic groups. Further study should better characterize factors influencing health-related GT uptake patterns.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.